Compare AANJANEYA LIFECARE with Fresenius Kabi Onco. - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. DATSONS LABS vs FRESENIUS KABI ONCO. - Comparison Results

FRESENIUS KABI ONCO. 
   Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. DATSONS LABS FRESENIUS KABI ONCO. DR. DATSONS LABS/
FRESENIUS KABI ONCO.
 
P/E (TTM) x -10.9 22.1 - View Chart
P/BV x 0.2 3.1 5.2% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 DR. DATSONS LABS   FRESENIUS KABI ONCO.
EQUITY SHARE DATA
    DR. DATSONS LABS
Mar-14
FRESENIUS KABI ONCO.
Mar-13
DR. DATSONS LABS/
FRESENIUS KABI ONCO.
5-Yr Chart
Click to enlarge
High Rs126176 71.4%   
Low Rs3179 39.4%   
Sales per share (Unadj.) Rs133.037.7 352.9%  
Earnings per share (Unadj.) Rs0.25.1 3.0%  
Cash flow per share (Unadj.) Rs6.66.7 98.3%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs128.842.5 302.7%  
Shares outstanding (eoy) m31.66158.23 20.0%   
Bonus/Rights/Conversions FCCB--  
Price / Sales ratio x0.63.4 17.4%   
Avg P/E ratio x516.125.0 2,065.8%  
P/CF ratio (eoy) x11.818.9 62.6%  
Price / Book Value ratio x0.63.0 20.3%  
Dividend payout %00-   
Avg Mkt Cap Rs m2,47720,135 12.3%   
No. of employees `000NA1.2 0.0%   
Total wages/salary Rs m56703 8.0%   
Avg. sales/employee Rs ThNM5,176.2-  
Avg. wages/employee Rs ThNM610.4-  
Avg. net profit/employee Rs ThNM699.6-  
INCOME DATA
Net Sales Rs m4,2115,963 70.6%  
Other income Rs m7918 437.2%   
Total revenues Rs m4,2895,981 71.7%   
Gross profit Rs m5691,430 39.8%  
Depreciation Rs m204258 79.3%   
Interest Rs m430-26 -1,654.6%   
Profit before tax Rs m131,216 1.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m-20-   
Extraordinary Inc (Exp) Rs m0-68 0.0%   
Tax Rs m6342 1.8%   
Profit after tax Rs m5806 0.6%  
Gross profit margin %13.524.0 56.3%  
Effective tax rate %48.028.1 170.7%   
Net profit margin %0.113.5 0.8%  
BALANCE SHEET DATA
Current assets Rs m6,8525,102 134.3%   
Current liabilities Rs m6,7112,385 281.3%   
Net working cap to sales %3.345.6 7.4%  
Current ratio x1.02.1 47.7%  
Inventory Days Days161150 107.2%  
Debtors Days Days318113 281.1%  
Net fixed assets Rs m3,6735,148 71.3%   
Share capital Rs m317158 200.1%   
"Free" reserves Rs m3,7616,556 57.4%   
Net worth Rs m4,0786,732 60.6%   
Long term debt Rs m1,671952 175.5%   
Total assets Rs m12,63310,388 121.6%  
Interest coverage x1.0-45.8 -2.2%   
Debt to equity ratio x0.40.1 289.7%  
Sales to assets ratio x0.30.6 58.1%   
Return on assets %3.47.5 45.9%  
Return on equity %0.112.0 1.0%  
Return on capital %7.714.6 52.5%  
Exports to sales %22.974.5 30.7%   
Imports to sales %14.324.8 57.7%   
Exports (fob) Rs m9644,441 21.7%   
Imports (cif) Rs m6021,477 40.7%   
Fx inflow Rs m9645,298 18.2%   
Fx outflow Rs m6071,772 34.3%   
Net fx Rs m3573,525 10.1%   
CASH FLOW
From Operations Rs m1,3451,274 105.5%  
From Investments Rs m-2,256-1,204 187.3%  
From Financial Activity Rs m-1,200-196 611.8%  
Net Cashflow Rs m-2,111-126 1,671.2%  

Share Holding

Indian Promoters % 4.5 0.0 -  
Foreign collaborators % 0.0 81.0 -  
Indian inst/Mut Fund % 0.0 0.3 -  
FIIs % 1.4 9.6 14.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 94.1 9.1 1,034.1%  
Shareholders   20,807 42,599 48.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. DATSONS LABS With:   IPCA LABS  SANOFI INDIA  ALEMBIC PHARMA  PROCTER & GAMBLE HEALTH  NOVARTIS  

Compare DR. DATSONS LABS With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Flat; Wipro & Hindalco Industries Among Top Nifty Gainers(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended on a flat note.

Related Views on News

Nazara Technologies IPO: Should You Apply? (IPO)

Mar 17, 2021

Should you bet on this gaming company backed by ace investor Rakesh Jhunjhunwala?

Nazara Technologies IPO: Should You Apply? (IPO)

Mar 17, 2021

Should you bet on this gaming company backed by ace investor Rakesh Jhunjhunwala?

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

4 Stocks to Make Your Portfolio Immune to the Second Covid Wave(Profit Hunter)

Apr 6, 2021

Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.

An India Revival Stock I'm Bullish On...(Profit Hunter)

Apr 9, 2021

This could take India to the position of 3rd largest economy.

Why Did the Market Crash on Monday?(Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

A Unique Sector for Short-Term Profits(Fast Profits Daily)

Apr 12, 2021

This ignored sector could deliver big short-term profits.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

DR. DATSONS LABS SHARE PRICE


May 21, 2015 (Close)

TRACK DR. DATSONS LABS

  • Track your investment in DR. DATSONS LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DR. DATSONS LABS

DR. DATSONS LABS 8-QTR ANALYSIS

COMPARE DR. DATSONS LABS WITH

MARKET STATS